BIOTECH FORUM + SCANLAB 2006
Now only 5 days to kick-off of this years BioTech Forum 26 - 28 September!
The BioTech Forum has three legs Exhibition, Business Conference and Partnering:
Visit Medicon Valley Academy, members and partners at the Medicon Valley booth (C2-036). Here you can meet the following MVA members and partners: Ideon Science Park, SCION-DTU A/S, Scantox A/S, Genovis AB, PhaseOneTrials A/S, Wiborg, SARomics AB, Innovagen AB, Capio Diagnostik A/S, Medicon A/S, Medicon Valley Academy, Copenhagen Capacity, Region Skåne, Naturvetarförbundet. Read more
The Business Conference is initiated 27 September by the biotech investment visionary Steven Burrill. The conference will deal with R&D issues for modern medicines development, which have been pinpointed as essential for the Innovative Medicines Initiative, a proposed joint undertaking between EU and the European pharma industry during FP 7 to develop better medicines faster. See final conference programme (pdf) and register for the conference.
You can still join this year’s partnering event! The event will give you a unique opportunity to meet with potential business partners and investors from the global Life Science industry in pre-booked One-to-One meetings. More than 150 companies have registered for the partnering. See list of participating companies (pdf) and register for partnering event.
MVA HIGHLIGHTS AT THE BIOTECH FORUM
Invitation to reception at Biotech Forum + ScanLab 2006
26 September 2006 / 16-17 / Bella Center / Copenhagen
Medicon Valley Academy is happy to invite you to reception at the BioTech Forum + ScanLab 2006. The reception will take place at the Medicon Valley booth (C2-036). Here you will have the opportunity to meet companies and organisations from Medicon Valley. We look forward to meeting you!
Early Clinical Development of AntiCancer Drugs
27 September / Bella Center / Copenhagen
An afternoon seminar on practical issues relating to the early stages of drug development - from pre-clinical studies to the conduct of clinical phase I/II studies. The seminar is organised by the Section of Clinical Pharmacy, Pharmaceutical Society of Denmark in collaboration with Medicon Valley Academy and PhaseOneTrials A/S. Free participation for MVA members. Read more
FP7 workshop - Helping SMEs & Researchers prepare for FP7 European R&D projects
28 September / Bella Center / Copenhagen
The 7th Framework Programme (FP7) will be presented by the European Commission, as well as details on the assistance and services provided by the two organising networks SMEs go life science and Passport. An important benefit for participants will be to make valuable contacts to prepare for coming the FP7 calls for project proposals. Read more
Roundtable: Innovation financing of medical devices in Europe
28 September / Bella Center / Copenhagen
The Europe Innova – InJection round tables bring together senior European stakeholders from the medical devices – healthcare technology sector, to discuss hurdles to innovation, and especially innovation financing, and to suggest opportunities and solutions.
This round table is a unique possibility to meet not European medical devices or healthcare technology stakeholders but also to help influence public support of innovation in the health technology sector. Read more
MEMBER NEWS
Novo Nordisk launches the Changing Diabetes Bus World Tour in order to raise awareness on diabetes
Under the motto ‘a global drive to change diabetes’, a world leader in diabetes care, the Medicon Vlley Academy member Novo Nordisk, unveils a Changing Diabetes Bus. This bus is realising a one-and-a-half-year-long journey around the world. It is one of the more ambitious initiatives from Novo Nordisk to raise awareness about diabetes. Read more
Natimmune acquires Nya HAMLET Pharma
7 September NatImmune acquired Nya HAMLET Pharma, a privately held company based in Lund, Sweden. Nya HAMLET Pharma was founded by Catharina Svanborg, professor at University of Lund, and it specializes in development of protein-derived compounds for cancer treatment. NatImmune has acquired Nya HAMLET Pharma through the acquisition of the entire issued share capital. Read more
Zealand Pharma raises capital for development of drugs for heart and cancer patients
With a capital injection from existing shareholders of close to EUR 30 million Zealand Pharma has gained the financial strength to continue the development of its drugs for heart and cancer patients. Zealand also plans to bring several new drugs into clinical development. Zealand's management has been strengthened with the promotion of Jørgen Søberg Petersen, Chief Scientific Officer, to Executive Vice President and the recruitment of Peter Damsbo as Vice President, Drug Development. Read more
Novozymes no. 1 for sustainability
For the sixth year in a row Novozymes has taken the top position in the Dow Jones Sustainability Group Index in the biotech category – both in Europe and globally. ”It means a lot to us to top the index for the sixth year in a row," says Anna Lise Mortensen Grandjean, vice president for Sustainability Development and Stakeholder Communications. "Sustainable development plays a key role in our business strategy of delivering sustainable biological solutions, so it's gratifying that others too think that we're doing the right thing". Read more
Maxygen Initiates Phase I Clinical Trial for Maxy-G34
Maxygen has initiated a Phase I clinical trial in the United States to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of Maxy-G34, a next generation Granulocyte Colony Stimulating Factor (G-CSF) for the treatment of chemotherapy-induced neutropenia. The ongoing Phase I clinical trial is a double-blind placebo controlled dose escalation study in healthy male and female volunteers. Maxy-G34 is a PEGylated proprietary G-CSF variant designed to be administered as a single subcutaneous injection once per chemotherapy cycle. Read more
ACTIVITIES IN MEDICON VALLEY
Symposium on Semiconductor Nanowires
1-2 October / Lund / Sweden
The 2nd symposium on Semiconductor Nanowires will be held in Lund 1-2 October 2006. The symposium is arranged by the Nanometer Structure Consortium at Lund University and Pronano with sponsorship from the Swedish Research Council. Read more
Nordic Venture Summit- 4th Edition
9 October 2006 / Radisson SAS Scandinavia / Amager Boulevard / Copenhagen/ Denmark
For the 4th year in a row, promising high-tech growth companies from across the Nordic Region will meet in Copenhagen 9 October 2006 with many of Europe’s most active venture capital and corporate investors. The Nordic Venture Summit, organised by Europe Unlimited in association with Connect Denmark.
Medicon Valley Academy is happy to offer its members a 15 % reduction on the registration fee. Read more
Food and drug administration (FDA) seminar for the biopharma industry
October 11 - 12, 2006 / Copenhagen / Denmark
This year's FDA seminar will be held in Copenhagen. The seminar is designed to help industry professionals involved with the biotechnology and pharmaceutical industry to better understand the U.S. FDA structure, regulatory dynamics, and future performance drivers of the sector. Read more
INTERNATIONAL ACTIVITIES
Optimal Biomanufacturing & Process Analytical Technology
2 October / London / UK
An ideal opportunity to learn about the many aspects of biomanufacturing and to find out current best practice in our industry. Organised by SIK, The Nordic Biomanufacturing Network (NbiNet) and IChemE. Read more
BIOInvestor Forum
18 & 19 October / San Francisco / US
Join leading investors and management from top life sciences growth companies at BIO InvestorForum 2006 in San Francisco. The Trade Commission of Denmark, Los Angeles invites biotech companies from the Medicon Valley region to participate in this unique partnership, investor and networking event. Read more
NEW MVA MEMBERS - See complete membership list
Biolin AB- www.biolin.se
Biolin is a diversified group of technology based and development intense companies within life science. Our business concept is to be the dedicated and long-term owner of growing companies with high profitability potential, thereby generating a high return for our shareholders. The group is growing by organic growth in current operations, and through business development and acquisitions. Biolin currently consists of wholly-owned subsidiaries Q-Sense, Ospol, Hansa Medical and the partly owned company Integration Diagnostics.”
ReceptIcon - www.recepticon.com
ReceptIcon is a spin-out from a research collaboration between the University of Aarhus and the Max Delbrück Center for Molecular Medicine in Berlin. The company is based on research that led to the identification of a protein, Megalin, which mediates the kidney damage caused by many important and frequently used drugs. ReceptIcon has developed a number of compounds capable of blocking Megalin and thus preventing kidney damage. The Company’s investors include InnovationsKapital, INCUBA Venture, Dansk Erhvervsinvestering, VECATA A/S, and Østjysk Innovation.
Vækstfonden - www.vaekstfonden.dk
Vækstfonden is a financial organisation that contributes to the promotion of Danish business and trade.
The mission of Vækstfonden is to strengthen development and renewal in the Danish economy by procuring financing for promising projects in small- and medium-size businesses.
Vækstfonden finance projects that others hesitate to, and work actively to strengthen business networks.